Novavax Inc. (NVAX) announced after the bell Tuesday that its RSV F-protein recombinant nanoparticle vaccine candidate was highly immunogenic in a guinea pig model of maternal immunization. The stock is now up 0.43 on 57K shares.
Novavax climbed during the first half of the morning Tuesday and advanced further in the final 90 minutes of trade. The stock finished with a gain of 0.42 at $10.17.
For comments and feedback: editorial@rttnews.com